Abstract
Bempedoic acid is a new lipid-lowering drug that inhibits cholesterol biosynthesis in liver cells selectively. Results from phase 2 and phase 3 studies showed a complementary effect on LDL-cholesterol lowering when combining bempedoic acid and ezetimibe without increasing side effects. Moreover, bempedoic acid seems to represent a good treatment option for the management of hypercholesterolemia, especially in patients at increased risk of cardiovascular events, such as patients with impaired glucose metabolism, elderly patients, patients with prior acute coronary syndrome, and patients with familial hypercholesterolemia. Based on the scientific evidence, this paper provides practical recommendations on the management of hypercholesterolemia with bempedoic acid.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
